Intelligent Bio Solutions Profit Margin

The latest profit margin for GBS is -294.91% as of June 2026. That compares with -346.23% in the prior-year period — up 14.8% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Intelligent Bio Solutions's historical trend and sector peers before judging valuation or financial health.

Over the past year, GBS's profit margin moved from -346.23% to -294.91% — a 14.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intelligent Bio Solutions's valuation or profitability profile.

Against Healthcare companies, GBS currently prints -294.91% for profit margin, while the sector average sits near 21.34%. That is roughly 1482.3% below the sector mean. Large gaps often invite a closer look at Intelligent Bio Solutions's growth, margins, and balance sheet.

Profit Margin shows how effectively Intelligent Bio Solutions converts resources into returns. At -294.91%, GBS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -346.23% in the prior-year period — up 14.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GBS's profit margin (-294.91%), review year-over-year change from -346.23%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.